Rami Hannoush is a distinguished healthcare venture capitalist at Versant Ventures, specializing in early-stage biotech and life science investments. With over 18 years of experience in drug discovery and development, Hannoush has held various leadership roles at Genentech and co-founded EpiBiologics. He earned his PhD in Chemistry from McGill University and completed postdoctoral fellowships in Chemical Biology and Cell Biology at Harvard Medical School. His expertise spans peptides, proteins, small molecules, and nucleic acids, with a focus on target discovery and validation, peptide therapeutics, stem cell and cancer signaling, biochemical and cellular pharmacology, and assay development. Hannoush has published over 65 peer-reviewed articles, including a recent paper on small molecules that stimulate Wnt signaling and intestinal organoid growth. His investment interests cover a broad range of healthcare companies, particularly those developing novel therapeutics for oncology, immunology, metabolic, neurodegenerative, and neuropsychiatric diseases. As a venture partner at Versant Ventures and a board member at Stablix, Hannoush leads interdisciplinary teams in lead discovery and research biology to develop innovative therapeutics. His deep knowledge in protein drug delivery, long-acting delivery, and translational biology of Wnt signaling pathways underscores his significant contributions to the life sciences. Hannoush remains actively involved in the biotech community, participating in groups such as Clinical Research Professionals and Bay Area Biotech Hikes.